Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes (Paper June 15 2026)

Key Takeaways

• Lifestyle group reduced multimorbidity risk by 21% versus placebo.
• Metformin showed no significant effect on chronic disease accumulation.
• 43% lower risk of high‑cost disease combos with lifestyle program.
• Absolute difference: 5% fewer people develop ≥2 conditions over 21 years.
• Program required 150 min/week activity, <25% calories from fat, 7% weight loss.

Pulse Analysis

The Diabetes Prevention Program (DPP) was one of the first large‑scale trials to test whether lifestyle change could stave off type 2 diabetes. By linking the original cohort to Medicare data, researchers now have the longest randomized‑origin follow‑up for any preventive intervention, allowing them to assess multimorbidity—a cluster of chronic conditions that drives health care costs and functional decline. This methodological leap moves beyond single‑disease endpoints, offering a more realistic picture of how early interventions shape health trajectories over the life course.

The lifestyle arm’s impact was striking. Participants who adhered to at least 150 minutes of moderate activity weekly, reduced dietary fat below 25% of calories, and lost roughly 7% of body weight experienced a 21% relative reduction in developing two or more chronic diseases and a 25% reduction for three or more. In absolute terms, that translates to one fewer case of multimorbidity per 20 people—a modest but clinically meaningful shift given the high prevalence of chronic illness in older adults. From a policy perspective, scaling such programs could lower Medicare expenditures, especially by curbing expensive disease pairings like stroke, kidney failure, and heart failure.

Conversely, metformin—often touted in longevity circles—did not differ from placebo in preventing multimorbidity. This null finding tempers enthusiasm for repurposing the diabetes drug as a universal anti‑aging therapy and underscores the need for rigorous, long‑term outcome data before broad clinical adoption. Future research may explore whether different dosing, combination therapies, or targeted subpopulations could unlock any latent benefits, but for now the evidence reaffirms that sustained lifestyle modification remains the most reliable, scalable approach to healthy aging.